RIMAG GROUP (02522) plans to increase its capital to nearly one billion yuan for Yinghe Yimai.

RIMAG GROUP (02522) announced that on October 29, 2025, the company entered into a "Capital Increase and Subscription Agreement" with Shanghai Yinghe Yimai Intelligent Technology Co., Ltd. (Yinghe Yimai) and related parties, whereby the company subscribed to the increase in registered capital of Yinghe Yimai at a total cost of nearly one hundred million RMB. After this transaction is completed, the company's total equity stake in Yinghe Yimai will be further increased. The board of directors believes that medical imaging artificial intelligence, as the core development direction of the future in the medical technology field, is entering a golden stage of rapid market demand release. With the acceleration of medical digital transformation, the demand for precise and efficient imaging diagnosis in clinical settings is becoming increasingly urgent. The market space in this area will continue to expand with long-term growth potential. Yinghe Yimai's core business covers the operation of an intelligent service platform for the entire process of medical imaging, AI-assisted diagnostic technology, and digital imaging solutions. Its technological capabilities and product deployment are highly complementary to the company's existing imaging service ecosystem, and can drive deep integration of resources between both parties. This capital increase and increased equity stake are important measures for the company to implement the "trinity" strategy of medical imaging AI (medical imaging data + AI base model + imaging center scene) and are highly consistent with the long-term development plan of focusing on the medical imaging field. By strengthening the capital connection with Yinghe Yimai, the two sides can further activate a "twin incubation" development mechanism - the company's long-term accumulation of high-quality data resources in the imaging center information system, combined with Yinghe Yimai's AI technology iteration, form a two-way empowerment loop, fundamentally constructing a virtuous interactive development pattern from informationization to data, and then from data to AI capabilities. From a strategic value perspective, this investment will bring multiple enhancements to the company: in terms of industrial chain layout, leveraging Yinghe Yimai's technological advantages, the group will further improve its business chain, accelerate the transformation to a data-driven service model, and enhance its core competitive edge in the industry; in terms of service quality, relying on Yinghe Yimai's technological achievements, the diagnostic accuracy and efficiency of the group's imaging centers and cooperative medical institutions will be significantly improved to better meet clinical needs; in terms of market competition, this investment will help the group seize a more favorable position in the rapidly growing field of imaging AI, seize industry development opportunities, and achieve sustainable business growth. It is expected that this investment will strengthen the group's layout in the medical imaging industry chain, enhance the accuracy and efficiency of the group's imaging diagnostic services, empower existing businesses, gain strategic support points in the rapidly growing field of imaging AI, enhance the group's innovation capabilities and competitive advantages in smart medical solutions, and consolidate the company's leading position in the Chinese medical imaging AI field through the construction of a "data + algorithm + scene" full-link closed loop.